nach oben

Erschienen in:

14.06.2020 | Original paper

Barriers and facilitators to HPV vaccine uptake among US rural populations: a scoping review

verfasst von: Caryn E. Peterson, Abigail Silva, Hunter K. Holt, Alexandrina Balanean, Abigail H. Goben, Jon Andrew Dykens

Erschienen in: Cancer Causes & Control | Ausgabe 9/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Compared to US urban populations, rural residents have a higher incidence of HPV-related cancer and lower HPV vaccine coverage. This study determined what is known about barriers and facilitators to vaccine uptake in US rural settings.

Methods

A scoping review was conducted to describe individual, interpersonal, organizational, and community/societal barriers and facilitators to HPV vaccine initiation and completion among US rural populations and to identify gaps in the current research. A systematic search was conducted using PubMed/MEDLINE and CINAHL databases.

Results

A total of 1,083 abstracts were reviewed and 13 articles met the inclusion criteria. Major themes at the individual-level included caregiver and vaccine-recipient demographics, other immunizations received, pap test history, awareness/knowledge of cervical cancer, HPV vaccine, or HPV infection, attitudes and motivation to vaccinate, STD diagnosis, sexual behavior, cervical cancer history, contraceptive use, and cancer fatalism. Interpersonal themes focused on provider influence and communication, caregiver and peer influence, and social support for the caregiver. At the organizational-level, themes included health insurance, provider characteristics, school-based interventions, and provider/practice-based interventions. The only community/societal factor examined related to a social marketing campaign.

Conclusion

Additional research is needed on interpersonal, organizational, and community/societal factors, as well as an expanded focus on rural males. Future studies should account for rural heterogeneity by expanding the geographic areas studied. Our findings detailing factors found to be associated with HPV vaccine uptake will help inform future clinical, health services, and community research, as well as interventions and policy efforts.

Nur mit Berechtigung zugänglich

Satterwhite CL, Torrone E, Meites E et al (2013) Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2008. Sex Transm Dis 40:187–193. https://doi.org/10.1097/OLQ.0b013e318286bb53 CrossRefPubMed

Chesson HW, Dunne EF, Hariri S, Markowitz LE (2014) The estimated lifetime probability of acquiring human papillomavirus in the United States. Sex Transm Dis 41:660–664. https://doi.org/10.1097/OLQ.0000000000000193 CrossRefPubMedPubMedCentral

Center for Disease Control and Prevention (CDC) (2019) Genital HPV infection—fact sheet. https://www.cdc.gov/std/hpv/stdfact-hpv.htm. Accessed 2 Apr 2020

Park IU, Introcaso C, Dunne EF (2015) Human papillomavirus and genital warts: a review of the evidence for the 2015 centers for disease control and prevention sexually transmitted diseases treatment guidelines. Clin Infect Dis 61(Suppl 8):S849–855. https://doi.org/10.1093/cid/civ813 CrossRefPubMed

Maxwell JH, Grandis JR, Ferris RL (2016) HPV-Associated head and neck cancer: unique features of epidemiology and clinical management. Annu Rev Med 67:91–101. https://doi.org/10.1146/annurev-med-051914-021907 CrossRefPubMed

Bosch FX, Manos MM, Muñoz N et al (1995) Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 87:796–802. https://doi.org/10.1093/jnci/87.11.796 CrossRefPubMed

Walboomers JM, Jacobs MV, Manos MM et al (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189:12–19. https://doi.org/10.1002/(SICI)1096-9896(199909)189:1<12:AID-PATH431>3.0.CO;2-F CrossRefPubMed

De Vuyst H, Clifford GM, Nascimento MC et al (2009) Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer 124:1626–1636. https://doi.org/10.1002/ijc.24116 CrossRefPubMed

Alemany L, Cubilla A, Halec G et al (2016) Role of human papillomavirus in penile carcinomas worldwide. Eur Urol 69:953–961. https://doi.org/10.1016/j.eururo.2015.12.007 CrossRefPubMed

10.

Schiffman M, Castle PE (2005) The promise of global cervical-cancer prevention. N Engl J Med 353:2101–2104. https://doi.org/10.1056/NEJMp058171 CrossRefPubMed

11.

Saraiya M, Unger ER, Thompson TD et al (2015) US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines. J Natl Cancer Inst. https://doi.org/10.1093/jnci/djv086 CrossRefPubMedPubMedCentral

12.

Garland SM, Steben M, Sings HL et al (2009) Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis 199:805–814. https://doi.org/10.1086/597071 CrossRefPubMed

13.

Drolet M, Bénard É, Pérez N et al (2019) Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet 394:497–509. https://doi.org/10.1016/S0140-6736(19)30298-3 CrossRefPubMedPubMedCentral

14.

(2019) ACIP HPV Vaccine Recommendations|CDC. https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/hpv.html. Accessed 2 Apr 2020

15.

Walker TY, Elam-Evans LD, Yankey D et al (2018) National, regional, state, and selected local area vaccination coverage among adolescents aged 13–17 years—United States, 2017. MMWR Morb Mortal Wkly Rep 67:909–917CrossRefPubMedPubMedCentral

16.

Hirth J (2019) Disparities in HPV vaccination rates and HPV prevalence in the United States: a review of the literature. Hum Vaccine Immunother 15:146–155. https://doi.org/10.1080/21645515.2018.1512453 CrossRef

17.

Spencer JC, Calo WA, Brewer NT (2019) Disparities and reverse disparities in HPV vaccination: a systematic review and meta-analysis. Prev Med 123:197–203. https://doi.org/10.1016/j.ypmed.2019.03.037 CrossRefPubMedPubMedCentral

18.

Walker TY, Elam-Evans LD, Singleton JA et al (2017) National, regional, state, and selected local area vaccination coverage among adolescents aged 13–17 years—United States, 2016. MMWR Morb Mortal Wkly Rep 66:874–882. https://doi.org/10.15585/mmwr.mm6633a2 CrossRefPubMedPubMedCentral

19.

Crosby RA, Casey BR, Vanderpool R et al (2011) Uptake of free HPV vaccination among young women: a comparison of rural versus urban rates. J Rural Health 27:380–384. https://doi.org/10.1111/j.1748-0361.2010.00354.x CrossRefPubMedPubMedCentral

20.

Zahnd WE, James AS, Jenkins WD et al (2017) Rural-urban differences in cancer incidence and trends in the United States. Cancer Epidemiol Biomark Prev. https://doi.org/10.1158/1055-9965.EPI-17-0430 CrossRef

21.

Reiter PL, Fisher JL, Hudson AG et al (2013) Assessing the burden of HPV-related cancers in Appalachia. Hum Vaccine Immunother 9:90–96. https://doi.org/10.4161/hv.22389 CrossRef

22.

Viens LJ, Henley SJ, Watson M et al (2016) Human papillomavirus-associated cancers—United States, 2008–2012. MMWR Morb Mortal Wkly Rep 65:661–666. https://doi.org/10.15585/mmwr.mm6526a1 CrossRefPubMed

23.

Mattson J (2011) Transportation, distance, and health care utilization for older adults in rural and small urban areas. Transp Res Rec. https://doi.org/10.3141/2265-22 CrossRef

24.

Buzza C, Ono SS, Turvey C et al (2011) Distance is relative: unpacking a principal barrier in rural healthcare. J Gen Intern Med 26(Suppl 2):648–654. https://doi.org/10.1007/s11606-011-1762-1 CrossRefPubMedPubMedCentral

25.

Hung P, Henning-Smith CE, Casey MM, Kozhimannil KB (2017) Access To obstetric services in rural counties still declining, with 9 percent losing services, 2004–14. Health Aff (Millwood) 36:1663–1671. https://doi.org/10.1377/hlthaff.2017.0338 CrossRef

26.

Douthit N, Kiv S, Dwolatzky T, Biswas S (2015) Exposing some important barriers to health care access in the rural USA. Public Health 129:611–620. https://doi.org/10.1016/j.puhe.2015.04.001 CrossRefPubMed

27.

Befort CA, Nazir N, Engelman K, Choi W (2013) Fatalistic cancer beliefs and information sources among rural and urban adults in the USA. J Cancer Educ 28:521–526. https://doi.org/10.1007/s13187-013-0496-7 CrossRefPubMedPubMedCentral

28.

Basu S, Berkowitz SA, Phillips RL et al (2019) Association of primary care physician supply with population mortality in the United States, 2005–2015. JAMA Intern Med 179:506–514. https://doi.org/10.1001/jamainternmed.2018.7624 CrossRefPubMedPubMedCentral

29.

(2014) ACOG Committee Opinion No. 586: Health disparities in rural women. Obstet Gynecol 123:384–388. https://doi.org/10.1097/01.AOG.0000443278.06393.d6

30.

Lu N, Samuels ME, Kletke PR, Whitler ET (2010) Rural-urban differences in health insurance coverage and patterns among working-age adults in Kentucky. J Rural Health 26:129–138. https://doi.org/10.1111/j.1748-0361.2010.00274.x CrossRefPubMed

31.

Zimmermann K, Carnahan LR, Paulsey E, Molina Y (2016) Health care eligibility and availability and health care reform: are we addressing rural women’s barriers to accessing care? J Health Care Poor Underserved 27:204–219. https://doi.org/10.1353/hpu.2016.0177 CrossRefPubMedPubMedCentral

32.

Weigel PAM, Ullrich F, Shane DM, Mueller KJ (2016) Variation in primary care service patterns by rural-urban location. J Rural Health 32:196–203. https://doi.org/10.1111/jrh.12146 CrossRefPubMed

33.

Fernández ME, Allen JD, Mistry R, Kahn JA (2010) Integrating clinical, community, and policy perspectives on human papillomavirus vaccination. Annu Rev Public Health 31:235–252. https://doi.org/10.1146/annurev.publhealth.012809.103609 CrossRefPubMedPubMedCentral

34.

Arksey H, O’Malley L (2005) Scoping studies: towards a methodological framework. Int J Soc Res Methodol 8:19–32. https://doi.org/10.1080/1364557032000119616 CrossRef

35.

Levac D, Colquhoun H, O’Brien KK (2010) Scoping studies: advancing the methodology. Implement Sci 5:69. https://doi.org/10.1186/1748-5908-5-69 CrossRefPubMedPubMedCentral

36.

Bhatta MP, Phillips L (2015) Human papillomavirus vaccine awareness, uptake, and parental and health care provider communication among 11- to 18-year-old adolescents in a rural Appalachian Ohio county in the United States. J Rural Health 31:67–75. https://doi.org/10.1111/jrh.12079 CrossRefPubMed

37.

Casey BR, Crosby RA, Vanderpool RC et al (2013) Predictors of initial uptake of human papillomavirus vaccine uptake among rural Appalachian young women. J Prim Prev 34:71–80. https://doi.org/10.1007/s10935-013-0295-2 CrossRefPubMedPubMedCentral

38.

Cates JR, Shafer A, Diehl SJ, Deal AM (2011) Evaluating a county-sponsored social marketing campaign to increase mothers’ initiation of HPV vaccine for their pre-teen daughters in a primarily rural area. Soc Mar Q 17:4–26. https://doi.org/10.1080/15245004.2010.546943 CrossRefPubMedPubMedCentral

39.

Chung RJ, Walter EB, Kemper AR, Dayton A (2015) Keen on teen vaccines: improvement of adolescent vaccine coverage in rural North Carolina. J Adolesc Health 56:S14–16. https://doi.org/10.1016/j.jadohealth.2014.10.272 CrossRefPubMed

40.

Vanderpool RC, Cohen E, Crosby RA et al (2013) “1-2-3 Pap” intervention improves HPV vaccine series completion among Appalachian women. J Commun 63:95–115. https://doi.org/10.1111/jcom.12001 CrossRefPubMedPubMedCentral

41.

Kepka DL, Ulrich AK, Coronado GD (2012) Low knowledge of the three-dose HPV vaccine series among mothers of rural Hispanic adolescents. J Health Care Poor Underserv 23:626–635. https://doi.org/10.1353/hpu.2012.0040 CrossRef

42.

Mills L, Vanderpool R, Crosby R (2011) Sexually related behaviors as predictors of HPV vaccination among young rural women. J Womens Health (Larchmt). https://doi.org/10.1089/jwh.2011.3000 CrossRef

43.

Reiter PL, Brewer NT, Gottlieb SL et al (2009) Parents’ health beliefs and HPV vaccination of their adolescent daughters. Soc Sci Med 69:475–480. https://doi.org/10.1016/j.socscimed.2009.05.024 CrossRefPubMed

44.

Vanderpool RC, Breheny PJ, Tiller PA et al (2015) Implementation and evaluation of a school-based human papillomavirus vaccination program in rural kentucky. Am J Prev Med 49:317–323. https://doi.org/10.1016/j.amepre.2015.05.001 CrossRefPubMed

45.

Vanderpool RC, Dressler EVM, Stradtman LR, Crosby RA (2015) Fatalistic beliefs and completion of the HPV vaccination series among a sample of young Appalachian Kentucky women. J Rural Health 31:199–205. https://doi.org/10.1111/jrh.12102 CrossRefPubMedPubMedCentral

46.

Vanderpool RC, Casey BR, Crosby RA (2011) HPV-related risk perceptions and HPV vaccine uptake among a sample of young rural women. J Community Health 36:903–909. https://doi.org/10.1007/s10900-010-9345-3 CrossRefPubMed

47.

Bednarczyk RA, Whitehead JL, Stephenson R (2017) Moving beyond sex: assessing the impact of gender identity on human papillomavirus vaccine recommendations and uptake among a national sample of rural-residing LGBT young adults. Papillomavirus Res 3:121–125. https://doi.org/10.1016/j.pvr.2017.04.002 CrossRefPubMedPubMedCentral

48.

Lai D, Ding Q, Bodson J et al (2016) Factors associated with increased HPV vaccine use in rural-frontier U.S. States. Public Health Nurs 33:283–294. https://doi.org/10.1111/phn.12223 CrossRefPubMed

49.

Lichter DT (2012) Immigration and the new racial diversity in rural America. Rural Sociol 77:3–35. https://doi.org/10.1111/j.1549-0831.2012.00070.x CrossRefPubMedPubMedCentral

50.

James CV, Moonesinghe R, Wilson-Frederick SM et al (2017) Racial/ethnic health disparities among rural adults—United States, 2012–2015. MMWR Surveill Summ 66:1–9. https://doi.org/10.15585/mmwr.ss6623a1 CrossRefPubMedPubMedCentral

51.

Caldwell JT, Ford CL, Wallace SP et al (2016) Intersection of living in a rural versus urban area and race/ethnicity in explaining access to health care in the United States. Am J Public Health 106:1463–1469. https://doi.org/10.2105/AJPH.2016.303212 CrossRefPubMedPubMedCentral

52.

Walker TY, Elam-Evans LD, Yankey D et al (2019) National, regional, state, and selected local area vaccination coverage among adolescents aged 13–17 years—United States, 2018. MMWR Morb Mortal Wkly Rep 68:718–723. https://doi.org/10.15585/mmwr.mm6833a2 CrossRefPubMedPubMedCentral

53.

Gilkey MB, Moss JL, McRee A-L, Brewer NT (2012) Do correlates of HPV vaccine initiation differ between adolescent boys and girls? Vaccine 30:5928–5934. https://doi.org/10.1016/j.vaccine.2012.07.045 CrossRefPubMedPubMedCentral

54.

Shah PD, Calo WA, Marciniak MW et al (2018) Support for pharmacist-provided HPV vaccination: national surveys of U.S. physicians and parents. Cancer Epidemiol Biomark Prev 27:970–978. https://doi.org/10.1158/1055-9965.EPI-18-0380 CrossRef

55.

Shah PD, Gilkey MB, Pepper JK et al (2014) Promising alternative settings for HPV vaccination of US adolescents. Expert Rev Vaccines 13:235–246. https://doi.org/10.1586/14760584.2013.871204 CrossRefPubMedPubMedCentral

56.

Vercruysse J, Chigurupati NL, Fung L et al (2016) Parents’ and providers’ attitudes toward school-located provision and school-entry requirements for HPV vaccines. Hum Vaccine Immunother 12:1606–1614. https://doi.org/10.1080/21645515.2016.1140289 CrossRef

57.

Moss JL, Feld AL, O’Malley B et al (2014) Opportunities for increasing human papillomavirus vaccine provision in school health centers. J Sch Health 84:370–378. https://doi.org/10.1111/josh.12158 CrossRefPubMedPubMedCentral

58.

Calo WA, Shah PD, Gilkey MB et al (2019) Implementing pharmacy-located HPV vaccination: findings from pilot projects in five U.S. states. Hum Vaccine Immunother 15:1831–1838. https://doi.org/10.1080/21645515.2019.1602433 CrossRef

59.

Islam JY, Gruber JF, Kepka D et al (2019) Pharmacist insights into adolescent human papillomavirus vaccination provision in the United States. Hum Vaccine Immunother 15:1839–1850. https://doi.org/10.1080/21645515.2018.1556077 CrossRef

60.

Calo WA, Gilkey MB, Shah PD et al (2016) Parents’ support for school-entry requirements for human papillomavirus vaccination: a national study. Cancer Epidemiol Biomark Prev 25:1317–1325. https://doi.org/10.1158/1055-9965.EPI-15-1159 CrossRef

61.

Robitz R, Gottlieb SL, De Rosa CJ et al (2011) Parent attitudes about school requirements for human papillomavirus vaccine in high-risk communities of Los Angeles, California. Cancer Epidemiol Biomark Prev 20:1421–1429. https://doi.org/10.1158/1055-9965.EPI-10-1236 CrossRef

62.

Gessert C, Waring S, Bailey-Davis L et al (2015) Rural definition of health: a systematic literature review. BMC Public Health 15:378. https://doi.org/10.1186/s12889-015-1658-9 CrossRefPubMedPubMedCentral

63.

Weinert C, Long KA (1987) Understanding the health care needs of rural families. Fam Relat 36:450–455. https://doi.org/10.2307/584499 CrossRef

64.

Deskins S, Harris CV, Bradlyn AS et al (2006) Preventive care in Appalachia: use of the theory of planned behavior to identify barriers to participation in cholesterol screenings among West Virginians. J Rural Health 22:367–374. https://doi.org/10.1111/j.1748-0361.2006.00060.x CrossRefPubMed

65.

Markowitz LE, Drolet M, Perez N et al (2018) Human papillomavirus vaccine effectiveness by number of doses: systematic review of data from national immunization programs. Vaccine 36:4806–4815. https://doi.org/10.1016/j.vaccine.2018.01.057 CrossRefPubMed

66.

Kreimer AR, Sherman ME, Sahasrabuddhe VV, Safaeian M (2015) The case for conducting a randomized clinical trial to assess the efficacy of a single dose of prophylactic HPV vaccines among adolescents. J Natl Cancer Inst. https://doi.org/10.1093/jnci/dju436 CrossRefPubMedPubMedCentral

67.

Kreimer AR, Herrero R, Sampson JN et al (2018) Evidence for single-dose protection by the bivalent HPV vaccine-review of the Costa Rica HPV vaccine trial and future research studies. Vaccine 36:4774–4782. https://doi.org/10.1016/j.vaccine.2017.12.078 CrossRefPubMedPubMedCentral

68.

Adjei Boakye E, Lew D, Muthukrishnan M et al (2018) Correlates of human papillomavirus (HPV) vaccination initiation and completion among 18–26 year olds in the United States. Hum Vaccine Immunother 14:2016–2024. https://doi.org/10.1080/21645515.2018.1467203 CrossRef

69.

Commission AR (2020) The Appalachian region—Appalachian regional commission. https://www.arc.gov/appalachian_region/theappalachianRegion.asp. Accessed 10 Apr 2020

70.

St Laurent J, Luckett R, Feldman S (2018) HPV vaccination and the effects on rates of HPV-related cancers. Curr Probl Cancer 42:493–506. https://doi.org/10.1016/j.currproblcancer.2018.06.004 CrossRefPubMed

Titel: Barriers and facilitators to HPV vaccine uptake among US rural populations: a scoping review
verfasst von: Caryn E. Peterson
Abigail Silva
Hunter K. Holt
Alexandrina Balanean
Abigail H. Goben
Jon Andrew Dykens
Publikationsdatum: 14.06.2020
Verlag: Springer International Publishing
Erschienen in: Cancer Causes & Control / Ausgabe 9/2020
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-020-01323-y

Neu im Fachgebiet Onkologie

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Das sind die führenden Symptome junger Darmkrebspatienten

23.05.2024 Leitsymptome in der Hausarztpraxis Nachrichten

Darmkrebserkrankungen in jüngeren Jahren sind ein zunehmendes Problem, das häufig längere Zeit übersehen wird, gerade weil die Patienten noch nicht alt sind. Welche Anzeichen Ärzte stutzig machen sollten, hat eine Metaanalyse herausgearbeitet.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Barriers and facilitators to HPV vaccine uptake among US rural populations: a scoping review